Juvisé Pharmaceuticals Acquires Multiple Sclerosis Drug PONVORY® (ex-US/Canada) and Opens Its Capital to Bpifrance and Pemberton
The French pharmaceutical company, Juvisé Pharmaceuticals, announces the acquisition of global commercial rights (excluding the United States and Canada) to Ponvory® (ponesimod) from Actelion Pharmaceuticals Ltd., a Johnson & Johnson Company (Johnson & Johnson). Ponvory® is indicated for the treatment of adults with active forms of relapsing multiple sclerosis (RMS); it is protected by several patents, the latest of which expires in 2035. To fund this acquisition, the French sovereign fund Bpifrance and Pemberton Asset Management (‘Pemberton’), a leading European private credit manager, have acquired a minority stake in Juvisé Pharmaceuticals. Financial details of these transactions remain undisclosed.
“We are very excited about Ponvory® and its potential to have a very positive impact on the lives of patients with multiple sclerosis” announces Frédéric Mascha, founder and President of Juvisé Pharmaceuticals. “This acquisition is a strategic step for Juvisé as it expands our portfolio with the first patent protected product with strong development potential over the coming years. It is in line with what we have been doing for the past 16 years, which is providing essential medications to patients and specialist doctors. Following our latest partnerships established with Novartis, AstraZeneca and AbbVie, we are proud to establish a new partnership with a major pharmaceutical company and to have two strong partners such as Bpifrance and Pemberton enter our capital to support our future growth.”
The acquisition of Ponvory®: a strategic move in Juvisé Pharmaceuticals' growth strategy
Multiple Sclerosis (MS) is a chronic autoimmune pathology affecting over 2.5 million patients worldwide and enjoys therapeutic innovation.
Ponvory® (ponesimod) is a first-line treatment option in active forms of relapsing multiple sclerosis (RMS), which is the most common form of the disease (approximately 80% of patients), affecting particularly women around the age of 30-years-old. Ponvory® is the first oral Disease Modifying Treatment (DMT) to demonstrate superior efficacy compared to teriflunomide in a large head-to-head Phase III study (OPTIMUM) in adult patients with active RMS. Ponvory® demonstrated a 30.5% reduction in Annualized Relapse Rate (primary endpoint), as well as reduction in MRI activity and fatigue (secondary endpoints). (1)
Juvisé Pharmaceuticals will leverage its expertise in medical affairs, marketing, and distribution to commercialize and develop Ponvory® outside of the United States and Canada, with a focus on Europe, skills that the company has already demonstrated with the successful European relaunch of Pylera® in 2023. Juvisé Pharmaceuticals will work closely with Johnson & Johnson to ensure a seamless transition and continuous availability of Ponvory® for patients. Ponvory® is currently available in 30 countries, with the objective of expanding this scope. Finally, Juvisé Pharmaceuticals will assume the worldwide manufacturing duties for Ponvory® from sites based in France and Switzerland.
Juvisé Pharmaceuticals opens its capital to Bpifrance and Pemberton
The acquisition of Ponvory® is funded by a mix of capital increase, additional debt, and shareholder loan.
Bpifrance, the French sovereign fund financing businesses in their development, and Pemberton, a leading European private credit manager, have acquired a minority stake in Juvisé as part of the transaction.
About Juvisé Pharmaceuticals
Since its creation in 2008, Juvisé Pharmaceuticals has played a pivotal role in enhancing patient care by providing access to treatments with high medical value. Juvisé re-prioritized essential medicines in oncology (breast and prostate cancer), cardiology, gastroenterology, neuropsychiatry, and rheumatology, making them accessible to over 4.4 million patients every year. Juvisé Pharmaceuticals is present through its products in 80 countries in the world on five continents and relocates the production of its acquired medications in Europe, with 81% being manufactured in Europe and 51% in France. In 2024, Juvisé Pharmaceuticals revenues are expected to reach about 180M€ (+38% vs 2023) with PONVORY® accounting for about 24%.
For more information, visit www.juvisepharmaceuticals.com
Lazard acted as financial advisor to Juvisé Pharmaceuticals and its shareholders.
Bird & Bird, Latham & Watkins and Bredin Prat acted as legal counsel to Juvisé Pharmaceuticals.
Société Générale remains the lead banking partner for Juvisé Pharmaceuticals.
1. Kappos L, Fox RJ, Burcklen M, Freedman MS, Havrdová EK, Hennessy B, Hohlfeld R, Lublin F, Montalban X, Pozzilli C, Scherz T, D'Ambrosio D, Linscheid P, Vaclavkova A, Pirozek-Lawniczek M, Kracker H, Sprenger T. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial. JAMA Neurol. 2021 May 1;78(5):558-567. doi: 10.1001/jamaneurol.2021.0405. PMID: 33779698; PMCID: PMC8008435
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240325471791/en/
Contact information
Juvisé Corporate communication contact
Caroline Tranvouez
Chief of staff to the CEO
+33 6 65 20 15 74
caroline.tranvouez@juvise.com
Media Relations contact
Nicolas Delaval
CLAI agency
+33 6 58 29 21 15
juvise@clai2.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Introducing Lasso: A New Food Tech Company Redefining Consumer Packaged Foods14.10.2025 20:34:00 EEST | Press release
Lasso today announced its official launch and the introduction of its proprietary technology, Lasso SpinTech. This breakthrough system upends the outdated standards of ultra-processed foods using physics to weave together protein and fiber to make previously unattainable new consumer products. With a new $6.5M raise, Lasso is bringing its technology to the world by launching its own brands and licensing to global partners to create a new generation of healthier foods. Guided by CEO Mike Messersmith, the Lasso team spent the past year deploying its commercial-scale technology to create innovative clean-label products including protein-packed snacks and pet food—expanding beyond its first plant-based meat application under the Tender Food brand. Lasso’s latest $6.5M in capital, led by Rhapsody Venture Partners with participation from Safar Partners, Claridge Venture Partners, and others, will enable the company to commercialize its transformative technology across new high growth food ca
Rimini Street to Report Third Quarter 2025 Financial Results on October 30, 202514.10.2025 19:00:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on October 30, 2025. The company will host a conference call and webcast on that date to discuss the third quarter and the 2025 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251014139026/en/ A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasdaq: RMNI), a Russell 2000® Company, is a proven,
Esri’s ArcGIS Maritime to Support Next-Generation S-100 Production Capabilities for Advanced Nautical Charting14.10.2025 19:00:00 EEST | Press release
Esri, the global leader in geographic information system (GIS) technology, announced new capabilities in ArcGIS Maritime to support production of S-100 compliant nautical charts, marking a major milestone in the evolution of hydrographic data management. Maritime organizations will also be able to generate S-57 charts alongside S-101 charts, which will enable them to more seamlessly leverage GIS. Crucial for supporting the latest spatial data and technologies, the shift to S-100 ready charting will enhance maritime navigation, safety, and situational awareness. The new S-100 series of standards developed by the International Hydrographic Organization (IHO) introduces a modern, extensible framework for electronic navigational charts, bathymetric data, and other marine information products. “The core mission of maritime authorities like hydrographic offices is supporting safe navigation, but they are increasingly being called upon to support broader priorities like the blue economy and e
Best-Selling Cessna Citation Latitude Reach Continues to Grow With First Order in Argentina14.10.2025 18:59:00 EEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company has announced the first order of its best-selling Cessna Citation Latitude in Argentina. The aircraft, which continues to grow in popularity, was ordered by longtime Citation customer, Jet Clipper S.A., a charter operator in Argentina also covering Uruguay and Paraguay; it is expected to be delivered in 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251014636481/en/ Best-selling Cessna Citation Latitude reach continues to grow with first order in Argentina (Photo Credit: Textron Aviation). “In a region where time and access are critical, the Citation Latitude’s range and short-field capabilities empower customers to reach remote destinations quickly and efficiently,” said Marcelo Moreira, vice president, Sales, Latin America. “The Latitude will support the customer's existing operations by offering the perfect balance of performance and comfort expected from a C
Veracode Named a Leader in the Gartner® Magic Quadrant™ Application Security Testing for 11 th Consecutive Time14.10.2025 18:48:00 EEST | Press release
Veracode, the global leader in application risk management, has once again been positioned as a Leader in the 2025 Gartner® Magic Quadrant™ for Application Security Testing (AST)¹. This marks the company’s 11th consecutive time as a Leader since the report was first published. The analysis represents one of the industry’s most in-depth and unbiased evaluations of market competitors. “Over nearly two decades, Veracode has earned a reputation as a trusted partner for thousands of organizations worldwide,” said Derek Maki, Senior Vice President & Head of Product at Veracode. “From pioneering security integration into the software development lifecycle to redefining AI-powered application risk management, we’ve always been at the forefront of innovation. We believe our continued position as a Leader in the Gartner Magic Quadrant reflects our unwavering commitment to customer success and the meaningful impact we deliver to business leaders, developers, and security teams every day. As AI fu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom